首頁 > 市場調查報告書 > 製藥

消化器

胃輕癱藥物市場規模、佔有率和成長分析（按類型、藥物類別、給藥途徑、應用、分銷管道和地區分類）—產業預測（2026-2033 年）

市場調查報告書

商品編碼

1897533

胃輕癱藥物市場規模、佔有率和成長分析（按類型、藥物類別、給藥途徑、應用、分銷管道和地區分類）—產業預測（2026-2033 年）

Gastroparesis Drugs Market Size, Share, and Growth Analysis, By Type (Branded, Generics), By Drug Class (Amino salicylates, Digestive enzymes), By Route of Administration, By Application, By Distribution Channel, By Region - Industry Forecast 2026-2033

出版日期: 2025年12月19日 | 出版商:

SkyQuest | 英文 192 Pages | 商品交期: 3-5個工作天內

價格

簡介目錄

全球胃輕癱藥物市場規模預計在 2024 年達到 60.1 億美元，從 2025 年的 63.4 億美元成長到 2033 年的 97.4 億美元，在預測期（2026-2033 年）內複合年成長率為 5.5%。

全球胃輕癱藥物市場持續穩定成長，主要受糖尿病盛行率上升（糖尿病是胃輕癱的主要誘因）以及人們對消化器官系統疾病日益成長的認知所驅動。此外，非侵入性、針對性治療方法的趨勢也促進了這一成長。質子幫浦阻斷劑和促動力藥物因其能有效緩解噁心和排放延遲等症狀，成為關鍵藥物類別。糖尿病性胃輕癱市場尤其突出，反映了糖尿病相關併發症的整體趨勢。儘管零售藥局仍然是主要的通路，但線上藥局因其便利性而日益受到關注。北美市場佔據主導地位，這得益於其完善的醫療保健體系、高診斷率和積極的監測機制；歐洲也貢獻顯著，尤其是在診斷技術和患者照護的進步。

全球胃輕癱藥物市場促進因素

推動全球胃輕癱藥物市場成長的關鍵因素之一是糖尿病盛行率的不斷上升，而糖尿病與胃輕癱密切相關。隨著全球1型和第2型糖尿病患者數量的增加，糖尿病性胃輕癱等併發症的發生率也在上升，增加了對治療的需求。這一趨勢促使製藥公司加強生產針對糖尿病性胃輕癱的標靶治療，凸顯了市場對有效解決方案的迫切需求，因為醫療保健機構正在努力應對這一疾病日益沉重的負擔。

全球胃輕癱藥物市場面臨的限制因素

全球胃輕癱藥物市場面臨許多挑戰，因為許多現有藥物主要針對緩解症狀，且可能產生不良副作用，導致長期使用受限，患者滿意度降低。監管環境也構成另一道障礙，許多新型候選療法因難以證明其足夠的長期安全性而受挫。這凸顯了開發創新且安全的胃輕癱療法的複雜性，並強調了推進能夠有效兼顧療效和耐受性的治療方案至關重要。

全球胃輕癱藥物市場趨勢

人工智慧（AI）在藥物研發和臨床試驗的應用是全球胃輕癱藥物市場的一大趨勢。 AI技術透過更精準地識別分子標靶和最佳化試驗設計以適應胃輕癱的複雜性，正在改善藥物研發環境。這種方法不僅有助於簡化藥物研發流程，還能降低成本並提高病患招募效率。隨著製藥公司積極採用AI驅動的調查方法，市場有望加速創新，並湧現出更多更有效的治療方案，最終加快新治療方法的研發，為飽受這種棘手疾病折磨的患者提供更完善的解決方案。

北美洲
- 美國
- 加拿大
歐洲
- 德國
- 西班牙
- 法國
- 英國
- 義大利
- 其他歐洲地區
亞太地區
- 中國
- 印度
- 日本
- 韓國
- 亞太其他地區
拉丁美洲
- 巴西
- 其他拉丁美洲地區
中東和非洲
- 海灣合作理事會國家
- 南非
- 其他中東和非洲地區

競爭資訊

前五大公司對比
主要企業的市場定位（2025 年）
主要市場參與者所採取的策略
近期市場趨勢
公司市佔率分析（2025 年）
主要企業公司簡介
- 公司詳情
- 產品系列分析
- 依業務板塊進行公司股票分析
- 2023-2025年營收年比比較

主要企業簡介

AbbVie Inc.（USA）
Evoke Pharma, Inc.（USA）
Vanda Pharmaceuticals Inc.（USA）
Takeda Pharmaceutical Company Limited（Japan）
AstraZeneca PLC（UK）
GlaxoSmithKline PLC（GSK）（UK）
Neurogastrx Inc.（USA）
Processa Pharmaceuticals, Inc.（USA）
Abbott Laboratories（USA）
Bausch Health Companies Inc.（Canada）
Rhythm Pharmaceuticals, Inc.（USA）
CinDome Pharma（USA）
ANI Pharmaceuticals, Inc.（USA）
Johnson & Johnson Inc.（USA）
Pfizer Inc.（USA）
Teva Pharmaceutical Industries Ltd.（Israel）
Medtronic PLC（Ireland）
Otsuka Pharmaceutical Co. Ltd.（Japan）
Theravance Biopharma, Inc.（USA）
Cadila Pharmaceuticals（India）

結論與建議

簡介目錄

Product Code: SQMIG35I2378

Global Gastroparesis Drugs Market size was valued at USD 6.01 Billion in 2024 and is poised to grow from USD 6.34 Billion in 2025 to USD 9.74 Billion by 2033, growing at a CAGR of 5.5% during the forecast period (2026-2033).

The global gastroparesis drugs market is witnessing consistent growth, largely fueled by the rising prevalence of diabetes, a major contributor to the condition, alongside increased awareness surrounding gastrointestinal issues. This growth is also supported by a shift towards non-invasive and symptom-specific therapies. Proton pump inhibitors and prokinetic agents are leading drug classes due to their efficacy in alleviating symptoms such as nausea and delayed gastric emptying. The diabetic gastroparesis segment is particularly prominent, reflecting the broader trend of diabetes-related complications. While retail pharmacies remain the primary distribution avenue, online pharmacies are gaining traction for their convenience. North America dominates the market, aided by robust healthcare systems, high diagnosis rates, and proactive research, with Europe also contributing significantly, particularly in diagnostics and patient care advancements.

Top-down and bottom-up approaches were used to estimate and validate the size of the Global Gastroparesis Drugs market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Global Gastroparesis Drugs Market Segments Analysis

Global Gastroparesis Drugs Market is segmented by Type, Drug Class, Route of Administration, Application, Distribution Channel and region. Based on Type, the market is segmented into Branded and Generics. Based on Drug Class, the market is segmented into Amino salicylates, Digestive enzymes, Proton Pump Inhibitors, Laxatives, Anti-Emetics, H2 Antagonists, Anti-Diarrheal, Biologics/Biosimilar and Others. Based on Route of Administration, the market is segmented into Oral, Injectable and Others. Based on Application, the market is segmented into Crohn's disease, Ulcerative colitis, GERD, IBS and Others. Based on Distribution Channel, the market is segmented into Hospital Pharmacies, Retail Pharmacies and Online Pharmacies. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.

Driver of the Global Gastroparesis Drugs Market

A significant factor propelling the global gastroparesis drugs market is the increasing prevalence of diabetes, which is intricately associated with gastroparesis. With a growing number of individuals diagnosed with both Type 1 and Type 2 diabetes around the world, the occurrence of complications such as diabetic gastroparesis is also rising, creating a greater demand for medical treatments. This trend encourages pharmaceutical companies to enhance their production of targeted therapies aimed at managing diabetic gastroparesis, highlighting the urgent need for effective solutions in the market as healthcare providers respond to the rising burden of this condition.

Restraints in the Global Gastroparesis Drugs Market

The Global Gastroparesis Drugs market faces significant challenges due to the fact that many existing medications primarily provide symptomatic relief and can lead to undesirable side effects, which in turn restricts their long-term usage and diminishes patient satisfaction. The regulatory landscape poses additional obstacles, as evidenced by the setbacks experienced by new treatment candidates that struggle to demonstrate adequate long-term safety. This underscores the complexities involved in developing innovative, safe therapies for gastroparesis and highlights the critical need for advancements in treatment options that can effectively address both efficacy and tolerability for patients.

Market Trends of the Global Gastroparesis Drugs Market

The Global Gastroparesis Drugs market is witnessing a significant trend towards the integration of artificial intelligence in drug discovery and clinical trials. AI technologies are enhancing the pharmaceutical R&D landscape by enabling more precise identification of molecular targets and optimizing trial designs tailored to the complexities of gastroparesis. This approach not only streamlines the drug development process but also reduces costs and improves patient enrollment efficiency. As pharmaceutical companies increasingly adopt AI-driven methodologies, the market is poised for accelerated innovation and more effective treatment options, ultimately leading to faster delivery of new therapies and an expanded repertoire of solutions for patients suffering from this challenging disorder.

Introduction

Objectives of the Study
Scope of the Report
Definitions

Research Methodology

Information Procurement
Secondary & Primary Data Methods
Market Size Estimation
Market Assumptions & Limitations

Executive Summary

Global Market Outlook
Supply & Demand Trend Analysis
Segmental Opportunity Analysis

Market Dynamics & Outlook

Market Overview
Market Size
Market Dynamics
- Drivers & Opportunities
- Restraints & Challenges
Porters Analysis
- Competitive rivalry
- Threat of substitute
- Bargaining power of buyers
- Threat of new entrants
- Bargaining power of suppliers

Key Market Insights

Key Success Factors
Degree of Competition
Top Investment Pockets
Market Ecosystem
Market Attractiveness Index, 2025
PESTEL Analysis
Macro-Economic Indicators
Value Chain Analysis
Pricing Analysis

Global Gastroparesis Drugs Market Size by Type & CAGR (2026-2033)

Market Overview
Branded
Generics

Global Gastroparesis Drugs Market Size by Drug Class & CAGR (2026-2033)

Market Overview
Amino salicylates
Digestive enzymes
Proton Pump Inhibitors
Laxatives
Anti-Emetics
H2 Antagonists
Anti-Diarrheal
Biologics/Biosimilar
Others

Global Gastroparesis Drugs Market Size by Route of Administration & CAGR (2026-2033)

Market Overview
Oral
Injectable
Others

Global Gastroparesis Drugs Market Size by Application & CAGR (2026-2033)

Market Overview
Crohn's disease
Ulcerative colitis
GERD
IBS
Others

Global Gastroparesis Drugs Market Size by Distribution Channel & CAGR (2026-2033)

Market Overview
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies

Global Gastroparesis Drugs Market Size & CAGR (2026-2033)

North America (Type, Drug Class, Route of Administration, Application, Distribution Channel)
- US
- Canada
Europe (Type, Drug Class, Route of Administration, Application, Distribution Channel)
- Germany
- Spain
- France
- UK
- Italy
- Rest of Europe
Asia Pacific (Type, Drug Class, Route of Administration, Application, Distribution Channel)
- China
- India
- Japan
- South Korea
- Rest of Asia-Pacific
Latin America (Type, Drug Class, Route of Administration, Application, Distribution Channel)
- Brazil
- Rest of Latin America
Middle East & Africa (Type, Drug Class, Route of Administration, Application, Distribution Channel)
- GCC Countries
- South Africa
- Rest of Middle East & Africa

Competitive Intelligence

Top 5 Player Comparison
Market Positioning of Key Players, 2025
Strategies Adopted by Key Market Players
Recent Developments in the Market
Company Market Share Analysis, 2025
Company Profiles of All Key Players
- Company Details
- Product Portfolio Analysis
- Company's Segmental Share Analysis
- Revenue Y-O-Y Comparison (2023-2025)

Key Company Profiles

AbbVie Inc. (USA)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Evoke Pharma, Inc. (USA)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Vanda Pharmaceuticals Inc. (USA)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Takeda Pharmaceutical Company Limited (Japan)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
AstraZeneca PLC (UK)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
GlaxoSmithKline PLC (GSK) (UK)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Neurogastrx Inc. (USA)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Processa Pharmaceuticals, Inc. (USA)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Abbott Laboratories (USA)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Bausch Health Companies Inc. (Canada)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Rhythm Pharmaceuticals, Inc. (USA)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
CinDome Pharma (USA)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
ANI Pharmaceuticals, Inc. (USA)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Johnson & Johnson Inc. (USA)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Pfizer Inc. (USA)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Teva Pharmaceutical Industries Ltd. (Israel)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Medtronic PLC (Ireland)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Otsuka Pharmaceutical Co. Ltd. (Japan)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Theravance Biopharma, Inc. (USA)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Cadila Pharmaceuticals (India)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments